142 related articles for article (PubMed ID: 19111045)
21. Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide.
French JT; Goins B; Saenz M; Li S; Garcia-Rojas X; Phillips WT; Otto RA; Bao A
J Vasc Interv Radiol; 2010 Aug; 21(8):1271-9. PubMed ID: 20478719
[TBL] [Abstract][Full Text] [Related]
22. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
23. Preliminary evaluation of acute toxicity of (188) Re-BMEDA-liposome in rats.
Liu CM; Chang CH; Chang YJ; Hsu CW; Chen LC; Chen HL; Ho CL; Yu CY; Chang TJ; Chiang TC; Lee TW
J Appl Toxicol; 2010 Oct; 30(7):680-7. PubMed ID: 20981861
[TBL] [Abstract][Full Text] [Related]
24. Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals.
Kostarelos K; Emfietzoglou D
Anticancer Res; 2000; 20(5A):3339-45. PubMed ID: 11062762
[TBL] [Abstract][Full Text] [Related]
25. 186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats.
Bao A; Goins B; Klipper R; Negrete G; Phillips WT
J Nucl Med; 2003 Dec; 44(12):1992-9. PubMed ID: 14660726
[TBL] [Abstract][Full Text] [Related]
26. A novel liposome radiolabeling method using 99mTc-"SNS/S" complexes: in vitro and in vivo evaluation.
Bao A; Goins B; Klipper R; Negrete G; Mahindaratne M; Phillips WT
J Pharm Sci; 2003 Sep; 92(9):1893-904. PubMed ID: 12950007
[TBL] [Abstract][Full Text] [Related]
27. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats.
Yokoe J; Sakuragi S; Yamamoto K; Teragaki T; Ogawara K; Higaki K; Katayama N; Kai T; Sato M; Kimura T
Int J Pharm; 2008 Apr; 353(1-2):28-34. PubMed ID: 18082345
[TBL] [Abstract][Full Text] [Related]
28. Translating Research for the Radiotheranostics of Nanotargeted
Chang CH; Chang MC; Chang YJ; Chen LC; Lee TW; Ting G
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918011
[TBL] [Abstract][Full Text] [Related]
29. [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model.
Soundararajan A; Bao A; Phillips WT; Perez R; Goins BA
Nucl Med Biol; 2009 Jul; 36(5):515-24. PubMed ID: 19520292
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
31. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models.
Peer D; Margalit R
Neoplasia; 2004; 6(4):343-53. PubMed ID: 15256056
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of doxorubicin encapsulated in poly(ethylene glycol)-coated liposomes.
Hosoda J; Unezaki S; Maruyama K; Tsuchiya S; Iwatsuru M
Biol Pharm Bull; 1995 Sep; 18(9):1234-7. PubMed ID: 8845812
[TBL] [Abstract][Full Text] [Related]
33. Radiopharmacokinetic and dosimetric parameters of 188Re-lanreotide in athymic mice with induced human cancer tumors.
Molina-Trinidad EM; de Murphy CA; Ferro-Flores G; Murphy-Stack E; Jung-Cook H
Int J Pharm; 2006 Mar; 310(1-2):125-30. PubMed ID: 16423478
[TBL] [Abstract][Full Text] [Related]
34. Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.
Soundararajan A; Bao A; Phillips WT; McManus LM; Goins BA
Cancer Biother Radiopharm; 2011 Oct; 26(5):603-14. PubMed ID: 21834653
[TBL] [Abstract][Full Text] [Related]
35. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model.
Lin YY; Li JJ; Chang CH; Lu YC; Hwang JJ; Tseng YL; Lin WJ; Ting G; Wang HE
Cancer Biother Radiopharm; 2009 Aug; 24(4):453-60. PubMed ID: 19694580
[TBL] [Abstract][Full Text] [Related]
37. Single dose acute toxicity testing for N,N-bis(2-mercaptoethyl)-N',N' diethylethylenediamine in beagles.
Liu SY; Chang CH; Lee TW
Regul Toxicol Pharmacol; 2014 Jul; 69(2):217-25. PubMed ID: 24721389
[TBL] [Abstract][Full Text] [Related]
38. Tumor-penetrating peptide mediation: an effective strategy for improving the transport of liposomes in tumor tissue.
Yan Z; Yang Y; Wei X; Zhong J; Wei D; Liu L; Xie C; Wang F; Zhang L; Lu W; He D
Mol Pharm; 2014 Jan; 11(1):218-25. PubMed ID: 24325555
[TBL] [Abstract][Full Text] [Related]
39. External beam radiotherapy synergizes ¹⁸⁸Re-liposome against human esophageal cancer xenograft and modulates ¹⁸⁸Re-liposome pharmacokinetics.
Chang CH; Liu SY; Chi CW; Yu HL; Chang TJ; Tsai TH; Lee TW; Chen YJ
Int J Nanomedicine; 2015; 10():3641-9. PubMed ID: 26056445
[TBL] [Abstract][Full Text] [Related]
40. Investigations on the antitumor efficacy of liposome-associated doxorubicin in murine tumor models.
Gabizon A; Goren D; Barenholz Y
Isr J Med Sci; 1988; 24(9-10):512-7. PubMed ID: 3204005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
